GlassScriptPhysician profile
Xihua Sun
NPI 1851326672
$9,823.67
in general payments reported to CMS, 2019-2025
32 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $668 · 2021: $1,838 · 2022: $1,157 · 2023: $1,353 · 2024: $1,182 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.81 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,802.22 | 2019-2025 | |
| Sk Life Science, INC. | $1,431.30 | 2021-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $1,140.24 | 2019-2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $730.05 | 2023-2025 | Fycompa |
| Emd Serono, INC. | $451.35 | 2019-2024 | Mavenclad |
| Adamas Pharmaceuticals, INC. | $450.60 | 2019-2021 | |
| Boston Scientific Corporation | $355.29 | 2020-2022 | |
| Amgen INC. | $313.98 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $313.94 | 2019 | |
| Akcea Therapeutics, INC. | $281.57 | 2019 | |
| Abbvie INC. | $280.22 | 2021-2024 | Qulipta |
| Biohaven Pharmaceuticals, INC. | $243.23 | 2021 | |
| Lundbeck LLC | $241.09 | 2019-2025 | Vyepti |
| Harmony Biosciences LLC | $235.08 | 2022-2023 | Wakix |
| Astrazeneca Pharmaceuticals LP | $194.68 | 2021-2024 | Andexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $187.66 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $161.06 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $160.44 | 2023 | Aptiom |
| Acadia Pharmaceuticals INC | $138.64 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $124.99 | 2021 | |
| Biogen, INC. | $124.52 | 2020-2023 | |
| Lilly USA, LLC | $79.37 | 2020-2023 | Amyvid |
| Avion Pharmaceuticals | $64.62 | 2021-2022 | |
| Allergan, INC. | $60.81 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $48.04 | 2019-2022 | |
| Ucb, INC. | $44.54 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.02 | 2022 | |
| Pfizer INC. | $31.97 | 2023 | |
| Mdd US Operations, LLC | $28.89 | 2019 | |
| Neurelis, INC. | $23.56 | 2021 | |
| Livanova USA, INC. | $22.40 | 2019 | |
| Portola Pharmaceuticals, LLC | $17.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xihua Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.